TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.330nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.640nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.700nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.820nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.80nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 1.90nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.30nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.40nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.40nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.60nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.70nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 2.80nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 3.10nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 3.20nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 3.40nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 3.60nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 3.90nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 6.30nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 6.90nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 8.20nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 8.30nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 8.40nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 8.60nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 9.60nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 9.70nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 10.2nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 10.2nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 11.7nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 13.5nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 13.9nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 19.9nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 25.6nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 28nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 29.1nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 29.6nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 35nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 37nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: 37nMAssay Description:Compounds were solubilized, and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5...More data for this Ligand-Target Pair